Last reviewed · How we verify

Telmisartan plus Captopril

Coordinación de Investigación en Salud, Mexico · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Telmisartan plus Captopril is a Small molecule drug developed by Coordinación de Investigación en Salud, Mexico. It is currently FDA-approved. Also known as: Capotena, Micardis.

Telmisartan is a small molecule that acts as a Type-1 angiotensin II receptor antagonist. It is used to treat hypertension and has been studied in various clinical trials for other conditions, including COVID-19, but its exact indications and effects are not specified in the provided facts.

At a glance

Generic nameTelmisartan plus Captopril
Also known asCapotena, Micardis
SponsorCoordinación de Investigación en Salud, Mexico
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Telmisartan plus Captopril

What is Telmisartan plus Captopril?

Telmisartan plus Captopril is a Small molecule drug developed by Coordinación de Investigación en Salud, Mexico.

Who makes Telmisartan plus Captopril?

Telmisartan plus Captopril is developed and marketed by Coordinación de Investigación en Salud, Mexico (see full Coordinación de Investigación en Salud, Mexico pipeline at /company/coordinaci-n-de-investigaci-n-en-salud-mexico).

Is Telmisartan plus Captopril also known as anything else?

Telmisartan plus Captopril is also known as Capotena, Micardis.

What development phase is Telmisartan plus Captopril in?

Telmisartan plus Captopril is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing